DOCSLIB.ORG

Indication Phase Route Country Name Role Country Type

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Indication Phase Route Country Name Role Country Type Alzheimer's Disease (Preclinical & Research) Drug Development Phase Organisations Drug Introduction Synonyms Mechanism Of Action Indication Phase Route Country Name Role Country Type Ownership IRX 4204 IRX 4204 is an orally bioavailable, first in class, AGN 194204 Retinoid X receptor agonists Prostate cancer Phase II PO USA Allergan Originator USA Large Pharma, Pharmaceutical Public retinoid X receptor (RXR; rexinoid) agonist being AGN-194204 Alzheimer's disease Preclinical PO USA Io Therapeutics Owner World Biopharmaceutical Private developed by Io Therapeutics. The initial focus is AGN194204 Parkinson's disease Preclinical PO USA Mount Sinai School of Medicine Collaborator USA University N/A for the treatment of castration-resistant prostate ALRT 4204 The Michael J. Fox Foundation for Parkinsons Research Collaborator USA Institution N/A cancer, but may also be developed for non-small cell lung cancer. IRX 4204 demonstrated activity ALRT-4204 against a variety of human cancers in vitro and ALRT4204 in animal models, including prostate, breast, IRX-4204 1 pancreatic, and lung [CONT.] IRX4204 NRX 194204 NRX 4204 NRX-194204 NRX-4204 NRX194204 NRX4204 VTP 194204 VTP-194204 VTP194204 Stem cell therapies - RNL BIO RNL BIO (South Korea) is researching and Adipose stem cell therapies - RNL BIO Cell replacements Facial hemiatrophy Phase II Parenteral South Korea Asan Medical Center Collaborator South Korea Hospital N/A developing stem cell therapies derived from adult Adult-derived stem cell therapies - RNL BIO Osteoarthritis Phase II Intra articular South Korea RNL BIO Originator South Korea Biotechnology sources, such as cord blood, placenta, hair Astrostem Thromboangiitis obliterans Phase II Parenteral South Korea RNL BIO Owner South Korea Biotechnology follicle and adipose (fat) tissue. The company is Autologous adipose stem cells - RNL BIO Intervertebral disc degeneration I/II Parenteral South Korea RST Biomedikal Sanayi Licensee Turkey Biotechnology focussing on the development of mesenchymal Cancerstem Osteonecrosis I/II Parenteral South Korea University of Newcastle upon Tyne Collaborator United Kingdom University N/A stem cell therapies derived from adipose fat. Clinical development is underway in Fat-derived stem cell therapies - RNL BIO Spinal cord injuries I/II Intraspinal South Korea osteonecrosis, interverterbral disc degeneration, Lipostem-DM Spinal cord injuries I/II Intrathecal South Korea 2 osteoarthritis, thromboangiitis obliterans, facial Lipostem-Femoran Spinal cord injuries I/II IV South Korea hemiatrophy, liver disorders, and spinal cord Mesenchymal stem cell therapies - RNL BIO Liver disorders Clinical IV Asia injury [CONT.] RNL-Astrostem™ Alzheimer's disease Preclinical IV South Korea RNL-JointStem® Cancer Preclinical Parenteral South Korea Vascostem™ Cerebral infarction Preclinical Parenteral South Korea Diabetes mellitus Preclinical Parenteral South Korea Fracture Preclinical Parenteral South Korea Ischaemic heart disorders Preclinical Intraventricular South Korea Adult neural stem cell therapy - StemCells is developing an adult neural stem cell hCNS-SC Cell replacements Age-related macular degeneration I/II Intraocular USA Oregon Health & Science University Collaborator USA University N/A StemCells therapy, known as HuCNS-SC®, for the treatment of disorders in all three regions of the HuCNS-SC Spinal cord injuries I/II Intraosseous Switzerland ReNeuron Technology Provider United Kingdom Biopharmaceutical Public CNS (brain, spinal cord, eyes). Researchers at 3 StemCells have succeeded in purifying stem cells HuCNS-SC cells Pelizaeus-Merzbacher disease Phase I Intracerebral USA StemCells Originator USA Biotechnology Public away from other cells in brain tissue by using HuCNS-SC® Alzheimer's disease Preclinical Parenteral USA StemCells Owner USA Biotechnology Public specific stem cell markers combined with state-of- Neurodegenerative disorders stem cell therapy - Stroke Preclinical Parenteral USA University of California at Irvine Collaborator USA University N/A the-art cell sorting. [CONT.] StemCells Neuronal ceroid lipofuscinosis Discontinued(I) Intracerebral USA Gene therapies - ReGenX Biosciences ReGenX Biosciences is developing personalised NAV™ therapeutics - ReGenX Biosciences Gene transference Haemophilia B I/II IV USA ARIAD Pharmaceuticals Collaborator USA Pharmaceutical Public gene therapies for eye, neurodegenerative, Neuronal ceroid lipofuscinosis Phase I Intracranial USA ARIAD Pharmaceuticals Technology Provider USA Pharmaceutical Public haematological and metabolic disorders, using its Age-related macular degeneration Preclinical Ophthalmic USA ReGenX Biosciences Originator USA Biopharmaceutical NAV™ gene delivery technology. NAV™ includes Alzheimer's disease Preclinical Parenteral USA ReGenX Biosciences Owner USA Biopharmaceutical a range of proprietary recombinant adeno- Haemophilia A Preclinical Parenteral USA St. Jude Childrens Research Hospital Collaborator USA Hospital N/A associated viral (rAAV) vectors, including rAAV7, Hypercholesterolaemia Preclinical Parenteral USA University of Pennsylvania Medical Center Collaborator USA University N/A 4 rAAV8, rAAV9 and rAAVrh10. [CONT.] Leber congenital amaurosis Preclinical Ophthalmic USA Weill Cornell Medical College Collaborator USA University N/A Metachromatic leukodystrophy Preclinical Intracranial USA Mucopolysaccharidosis I Preclinical Parenteral USA Mucopolysaccharidosis III Preclinical Intracranial USA Mucopolysaccharidosis VI Preclinical Parenteral USA Retinitis pigmentosa Preclinical Ophthalmic USA RNS 60 RNS 60 is a charge-stabilised nanostructure RNS-60 G protein-coupled receptor modulators Asthma (Combination therapy) I/II Inhalation USA Revalesio Originator USA Biotechnology Private (CSN) product that is in development with the biotechnology company Revalesio for the treatment of asthma and other neurological inflammatory disorders. CSNs are aqueous-based nano-bubble cores surrounded by a stable 5 molecular scaffolding that could alter whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, and RNS60 Ion channel modulators Asthma Phase I IV USA Revalesio Owner USA Biotechnology Private thereby modulating the expression of G-protein Myocardial infarction (In volunteers) Phase I IV USA Rush University Collaborator USA University N/A coupled receptors and secretion of cytokines, Alzheimer's disease Preclinical Unknown route USA chemokines and adhesion molecules [CONT.] Multiple sclerosis Preclinical IV USA Parkinson's disease Preclinical Unknown route USA Zinc monocysteine Synthetic Biologics (formerly Adeona AEN 100 Antioxidants Amyotrophic lateral sclerosis I/II PO USA Adeona Pharmaceuticals Originator USA Biotechnology Public Pharmaceuticals) is developing zinc-based therapeutics, including a proprietary formulation of orally available zinc monocysteine, for the treatment of Alzheimer's disease and 6 amyotrophic lateral sclerosis (ALS). The product was originally developed as a prescription medical food; however, following positive results AEN-100 Free radical scavengers Alzheimer's disease Preclinical PO USA Synthetic Biologics Owner USA Biotechnology Public from a 42 patient clinical study, the company AEN-100/AEN-200 Glutathione peroxidase stimulants now plans to develop the product as a reaZin™ prescription pharmaceutical [CONT.] Zinc cysteine - Adeona Neurological disorder stem cell Neuralstem is developing neural stem cells from Adult neural stem cells - Neuralstem Cell replacements Amyotrophic lateral sclerosis Phase I Intraspinal USA China Medical University Hospital Collaborator Taiwan Hospital N/A therapies - Neuralstem the human brain and spinal cord for the HNSC Alzheimer's disease Preclinical Unknown route USA CJ Cheiljedang Corp. Collaborator South Korea Biopharmaceutical treatment of a range of neurological disorders, HSSC Amyotrophic lateral sclerosis Preclinical Intraspinal Taiwan Emory University Collaborator USA University N/A including amyotrophic lateral sclerosis (ALS), NSI 566 Brain injuries Preclinical Unknown route USA Neuralstem Originator Usa Company Huntington's disease, ischaemic spastic NSI 566RSC Cerebral palsy Preclinical Unknown route USA Neuralstem Owner Usa Company paraplegia, stroke and traumatic spinal cord NSI-566 Diabetic neuropathies Preclinical Unknown route USA University of California, San Diego Technology Provider USA University N/A injuries. The company's patent-protected NSI-566RSC Huntington's disease Preclinical Unknown route Germany University of Freiburg Collaborator Germany University N/A 7 technology is used to control the differentiation NSI566 Lysosomal storage diseases Preclinical Unknown route USA of the stem cells into mature physiologically Multiple sclerosis Preclinical Unknown route USA relevant human neurons and glia, and to produce Optic neuritis Preclinical Unknown route USA commercial quantities of these cells [CONT.] Paraplegia Preclinical Unknown route USA Parkinson's disease Preclinical Unknown route USA Spinal cord injuries Preclinical Intraspinal South Korea, USA Stroke Preclinical Intracerebral China, USA NSI 189 Neuralstem is developing NSI 189, an orally NSI-189 Neurogenesis stimulants Major depressive disorder Phase I PO USA Neuralstem Originator Usa Company active, first-in-class, small molecule neurogenic therapeutic for the treatment of major depressive disorder. The compound can cross the blood- NSI-189 phosphate Alzheimer's disease Preclinical PO USA Neuralstem Owner Usa Company 8 brain barrier and
Load more

Recommended publications
  • Und Serumspiegel Von S-100B Und GFAP Nach Schädelhirntrauma: Aussagekraft in Der Akutdiagnostik Und Möglicher Prognostischer Wert
    Aus dem Institut für Neuroradiologie der Universität zu Lübeck Direktor: Prof. Dr. med. D. Petersen ______________________________________________________ Plasma- und Serumspiegel von S-100B und GFAP nach Schädelhirntrauma: Aussagekraft in der Akutdiagnostik und möglicher prognostischer Wert Inauguraldissertation zur Erlangung der Doktorwürde der Universität zu Lübeck - Aus der medizinischen Fakultät - vorgelegt von Elke Steinmeier aus Braunschweig Lübeck, 2006 Erster Berichterstatter Priv. Doz. Dr. med. Ulrich Missler Zweiter Berichterstatter/ Berichterstatterin Priv. Doz. Dr. med. Jan Gliemroth Tag der mündlichen Prüfung 03.05.2007 Zum Druck genehmigt Lübeck, den 03.05.07 gez. Prof. Dr. med. Werner Solbach Dekan der Medizinischen Fakultät 2 Inhalt Inhalt 3 1. Grundlagen 5 1.1 Einleitung und Fragestellung 5 1.2 Schädelhirntrauma 8 1.3 Zerebrale Strukturproteine 12 1.4 Das S-100 Protein 13 1.4.1 Vorkommen der S-100 Monomere 14 1.4.2 Funktion der S-100 Proteine 15 1.5 Das saure gliale Faserprotein (GFAP) 16 1.5.1 Vorkommen des GFAP im menschlichen Körper 16 1.5.2 Funktion des GFAP Proteins 16 2. Patienten, Material und Methoden 18 2.1 Auswahl von Patienten und Kontrollpersonen 18 2.2 Probengewinnung und Verarbeitung 18 2.3 Material 19 2.3.1 Antikörper 19 2.3.2 Chemikalien und verwendete Pufferlösungen 19 2.3.2.1 Herstellung der Enhancement-Lösung 19 2.3.2.2 Herstellung des Waschpuffers 20 2.3.2.3 Herstellung des TRIS/HCl/NaCl-Puffers 20 2.4 Immunfluoreszenzassay zur Bestimmung des S-100B Proteins 20 2.5 Immunfluoreszenzassay zur Bestimmung des GFAP Proteins 22 2.6 Neurologische Beurteilungsskalen 23 2.6.1 Glasgow Coma Skala 23 2.6.2 Glasgow Outcome Skala 25 2.6.3 CCT-Skala 25 2.7 Statistische Methoden 26 3.
    [Show full text]
  • Biomarkers for Ischaemic Stroke
    BIOMARKERS FOR ISCHAEMIC STROKE NAZEEHA HASAN A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY SUPERVISORS: DR PANKAJ SHARMA DR ROBERT EDWARDS DEPARTMENT OF MEDICINE IMPERIAL COLLEGE LONDON DECEMBER 2013 ABSTRACT Background: Current diagnostic, prognostic and risk stratification tools are inadequate for effective ischaemic stroke management. Hypothesising that –omics approaches can be used to detect novel candidate biomarkers for ischaemic stroke, this thesis aimed to evaluate the current status of biomarkers for ischaemic stroke and develop strategies for biomarker discovery. Methods: Systematic literature review and individual patient data meta-analyses were performed to assess current candidate biomarkers associated with ischaemic stroke. Proteomic SELDI-TOF MS profiling was undertaken to identify novel blood-based protein biomarkers for the diagnosis of acute ischaemic stroke, consisting of a pilot study and a subsequent well- powered discovery study of 104 patients. In an integrative genomics study, transcriptomics data from carotid endarterectomy samples was combined with a genome-wide association study meta-analysis and subjected to functional enrichment analysis to detect differential gene expression or alternative splicing profiles that may be under the control of a genetic variant. Results: Systematic review and meta-analysis concluded that no current candidate biomarkers could be recommended for routine clinical practice, supporting the pursuit of novel biomarkers for ischaemic stroke and informing the design of subsequent experimental studies. SELDI-TOF MS detected two plasma protein ions, m/z 3699 and m/z 6640, which could differentiate between acute cerebral ischaemia and stroke mimics. Protein ion m/z 6640, identified as ApoC-1, highlighted the role of lipid dysregulation and was postulated to be a novel candidate biomarker for acute cerebral ischaemia.
    [Show full text]
  • Mesh Terms for 2002
    Mesh Terms for Fiscal Year 2002 1,2-DIMETHYLHYDRAZINE 1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE 1,4-ALPHA-GLUCAN BRANCHING ENZYME 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE 1-ACYLGLYCEROPHOSPHOCHOLINE O-ACYLTRANSFERASE 1-BUTANOL 1-CARBOXYGLUTAMIC ACID 1-DEOXYNOJIRIMYCIN 1-METHYL-3-ISOBUTYLXANTHINE 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE 1-METHYL-4-PHENYLPYRIDINIUM 1-NAPHTHYLAMINE 1-NAPHTHYLISOTHIOCYANATE 1-OCTANOL 1-PHOSPHATIDYLINOSITOL 3-KINASE 1-PHOSPHATIDYLINOSITOL 4-KINASE 1-PROPANOL 1-SARCOSINE-8-ISOLEUCINE ANGIOTENSIN II 11-HYDROXYCORTICOSTEROIDS 12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID 15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOI 15-OXOPROSTAGLANDIN 13-REDUCTASE 16,16-DIMETHYLPROSTAGLANDIN E2 17 ALPHA-HYDROXYPROGESTERONE ALDOLASE 17-HYDROXYCORTICOSTEROIDS 17-HYDROXYPROGESTERONE 17-HYDROXYSTEROID DEHYDROGENASES 17-KETOSTEROIDS 18-HYDROXYCORTICOSTERONE 18-HYDROXYDESOXYCORTICOSTERONE 19-IODOCHOLESTEROL 2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES 2',5'-OLIGOADENYLATE SYNTHETASE 2,2'-DIPYRIDYL 2,3-DIKETOGULONIC ACID 2,3-DIPHOSPHOGLYCERATE 2,4,5-TRICHLOROPHENOXYACETIC ACID 2,4-DICHLOROPHENOXYACETIC ACID 2,4-DINITROPHENOL 2,5-DIMETHOXY-4-METHYLAMPHETAMINE 2,6-DICHLOROINDOPHENOL 2-ACETOLACTATE MUTASE 2-ACETYLAMINOFLUORENE 2-AMINO-5-PHOSPHONOVALERATE 2-AMINOADIPIC ACID 2-AMINOPURINE 2-CHLOROADENOSINE 2-DEHYDRO-3-DEOXYPHOSPHOHEPTONATE ALDOLASE 2-HYDROXY-5-NITROBENZYL BROMIDE 2-HYDROXYPHENETHYLAMINE 2-ISOPROPYLMALATE SYNTHASE 2-METHYL-4-CHLOROPHENOXYACETIC ACID 2-NAPHTHYLAMINE 2-PROPANOL 20-HYDROXYSTEROID DEHYDROGENASES
    [Show full text]
  • Insights from the Sequence Similarity of Zika Virus Proteins with the Human Nerve Proteins
    Open access www.bioinformation.net Hypothesis Volume 14(5) Insights from the sequence similarity of Zika virus proteins with the Human nerve proteins Prasanna Marsakatla1, Sujai Suneetha1, Joshua Lee2, Paari Dominic Swaminathan3, Logeshwaran Vasudevan4, Rachael Supriya1, Lavanya Moses Suneetha1* Received April 10, 2018; Revised April 23, 2018; Accepted April 30, 2018; Published May 31, 2018 1CODEWEL Nireekshana ACET, Narayanaguda, Hyderabad -500029, Telangana, India; 2York University, Department of Science, 4700 Keele St, Toronto, ON M3J 1P3, Canada; 3LSU Health Sciences Center, Center for Cardiovascular Diseases and Sciences Shreveport, LA, USA; 4Presidency College, Department of Zoology, Chennai-05, India; Lavanya Moses Suneetha – E:mail - [email protected]; Phone: +91-40-23221033; +91-9885150381; *Corresponding Author doi:10.6026/97320630014194 Abstract: Massive peptide sharing between the Zika virus polyprotein and host tissue proteins could elicit significant host-pathogen interactions and cross-reactions leading to autoimmune diseases. This study found similarities in the Zika V proteins and human nerve tissue proteins. 63 human nerve proteins were screened for similarities with the Zika V of which Neuromodulin, Nestin, Galanin, Bombesin, Calcium-binding protein were found to have similarities to the Zika V poly protein C at different sequence regions. These sequence similarities could be significant in regulating pathogenic interactions/autoimmunity, as Polyprotein C is known to be a virulent factor. Keywords: Zika V, Nerve tissue proteins, Neuropathogenesis, Bioinformatics, BLAST, Neuromodulin, Nestin, Bombesin, Galanin, Calcium-binding protein. Background: Tyro3, and TIM-1) facilitating the entry of the Zika V into The Zika Virus (Zika V), is an emerging infectious disease agent different tissue cells [7]. Cell culture experiments of the Zika V causing human birth defects.
    [Show full text]
  • Intiharin Biyokimyasal Belirteçleri Olarak Beyin Omurilik Sivisinda S100b Proteini Ve Serotonin Düzeylerinin Değerlendirilmesi
    T.C. SELÇUK ÜNİVERSİTESİ SAĞLIK BİLİMLERİ ENSTİTÜSÜ İNTİHARIN BİYOKİMYASAL BELİRTEÇLERİ OLARAK BEYİN OMURİLİK SIVISINDA S100B PROTEİNİ VE SEROTONİN DÜZEYLERİNİN DEĞERLENDİRİLMESİ Kamil Hakan DOĞAN DOKTORA TEZİ BİYOKİMYA (TIP) ANABİLİM DALI DANIŞMAN Prof. Dr. Mustafa ÜNALDI KONYA - 2012 T.C. SELÇUK ÜNİVERSİTESİ SAĞLIK BİLİMLERİ ENSTİTÜSÜ İNTİHARIN BİYOKİMYASAL BELİRTEÇLERİ OLARAK BEYİN OMURİLİK SIVISINDA S100B PROTEİNİ VE SEROTONİN DÜZEYLERİNİN DEĞERLENDİRİLMESİ Kamil Hakan DOĞAN DOKTORA TEZİ BİYOKİMYA (TIP) ANABİLİM DALI DANIŞMAN Prof. Dr. Mustafa ÜNALDI Bu araştırma Selçuk Üniversitesi Bilimsel Araştırma Projeleri Koordinatörlüğü tarafından 11102026 proje numarası ile desteklenmiştir. KONYA - 2012 ÖNSÖZ Adli Tıp Uzmanı olarak Biyokimya Anabilim Dalı’nda doktora eğitimine, Biyokimya biliminin Adli Tıp alanında pek çok yerde kullanılması ve Adli Tıp’ın gelişmesinde çok önemli bir yeri olması nedeniyle başladım. Eğitimim boyunca da, Biyokimya’nın derinliklerine indikçe, aslında rutinde Adli Tıp alanında kullandığımız pek çok bilginin tamamen biyokimyasal süreçlere ve temellere dayandığı ve bu alanda ilerlemenin ancak iyi bir biyokimya bilgisine ve nosyonuna sahip olmakla gerçekleştirilebileceğini daha iyi kavradım. Bu zorlu süreçte doktora eğitimim boyunca bilgi ve deneyimleri ile bana yol gösteren başta tez danışmanım kıymetli hocam Prof.Dr. Mustafa Ünaldı’ya, İlgisini ve desteğini sürekli hissettiğim Biyokimya Anabilim Dalı Başkanı kıymetli hocam Prof.Dr. İdris Mehmetoğlu’na, Eğitimime katkı sağlayan Biyokimya Anabilim Dalı’nın tüm değerli öğretim üyelerine ve laboratuvar personeline, Doktora çalışmasına başlamamda motivasyonumu sağlayan ve tez çalışmam boyunca örneklerin toplanmasına bizzat katkı sağlayan kıymetli hocam Doç.Dr.Şerafettin Demirci’ye, Örneklerin analizi aşamasında samimi desteğini gördüğüm Arş.Gör.Dr. Erkan Taşyürek’e, Bu çalışmanın yapılabilmesi için gerekli maddi desteği 11102026 nolu projeyle sağlayan Selçuk Üniversitesi Bilimsel Araştırma Projeleri Koordinatörlüğü’ne, Her zaman desteğini gördüğüm eşim Yrd.Doç.Dr.
    [Show full text]
  • Early Stage & Preclinical MOA Counts Early Stage & Preclinical Company
    Early Stage & Preclinical MOA counts Early Stage & Preclinical Company Activity MOA # of profiles Company # of profiles Aβ inhibitors 58 Merck & Co 12 Undefined 33 AstraZeneca 11 Immunostimulants 19 Pfizer 10 BACE1 protein inhibitors 18 Bristol-Myers Squibb 6 Tau protein inhibitors 13 Roche 6 APP secretase inhibitors 12 Wyeth 6 AChe inhibitors 8 GlaxoSmithKline 5 Alpha-synuclein inhibitors 7 Takeda 5 APP secretase modulators 7 University of California at Irvine 5 5-HT6 antagonists 7 Abbott Laboratories 4 Tau protein modulators 6 AbbVie 4 Amyloid beta-protein precursor inhibitors 5 Astellas Pharma 4 Antioxidants 5 Bayer HealthCare Pharmaceuticals 4 Cell replacements 5 Biogen Idec 4 Immunomodulators 5 Daewoong Pharmaceutical 4 NMDA receptor antagonists 5 Eli Lilly 4 Positron-emission tomography enhancers 5 Northwestern University 4 Alpha7 nicotinic acetylcholine receptor agonists 4 Suven Life Sciences 4 Amyloid inhibitors 4 Alzheimers Drug Discovery Foundation 3 Chelating agents 4 Boehringer Ingelheim 3 Nerve growth factor stimulants 4 CHDI 3 Neuron stimulants 4 ChemDiv 3 Serotonin 4 receptor agonists 4 Elan Corporation 3 Amyloid beta-protein modulators 3 EnVivo Pharmaceuticals 3 Calcium channel antagonists 3 JANSSEN Alzheimer Immunotherapy 3 Cathepsin S inhibitors 3 Johnson & Johnson Pharmaceutical Research & Development 3 G protein-coupled receptor modulators 3 Lay Line Genomics 3 Muscarinic M1 receptor agonists 3 Ligand Pharmaceuticals 3 Nicotinic receptor agonists 3 McGill University 3 Advanced glycosylation end-product receptor antagonists
    [Show full text]
  • William Nichol Whiteley
    Blood markers for the diagnosis and prognosis of stroke William Nichol Whiteley PhD by Research University of Edinburgh 2010 Whiteley W.N . Blood Markers in Stroke University of Edinburgh 2010 Table of contents Table of contents ................................................................................................................... 2 Table of tables........................................................................................................................ 7 Table of figures.................................................................................................................... 11 Abstract................................................................................................................................. 14 Declaration........................................................................................................................... 17 Publications and awards relating to the work of this thesis......................................... 18 Abbreviations ...................................................................................................................... 21 Acknowledgments and my contribution to the work of the thesis ............................. 24 Chapter 1. Introduction ............................................................................................... 26 The importance of diagnosis and prognosis ............................................................... 26 Aims of the thesis...........................................................................................................
    [Show full text]